Kidney Failure Chronic
📧 Sign up to get email alerts when something new happens for Kidney Failure Chronic.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-04EMA Authorised: Silapo (epoetin zeta) — Stada Arzneimittel AG
The EMA authorises Silapo (epoetin zeta) by Stada Arzneimittel AG for treating anemia associated with cancer, chronic kidney failure, and bl…
-
EMA approval · 2026-07-20EMA Authorised: Retacrit (epoetin zeta) — Pfizer Europe MA EEIG
Authorised status for Retacrit (epoetin zeta) by EMA for use in anemia-related indications, including kidney failure, cancer-related anemia,…
-
CLINICAL_TRIALS trial_result · 2023-02-09Clinical Trial Update: The Effect of Intravenous Iron Therapy and Erythropoiesis-stimulation Agent Combination on Renal Transplant Outcomes [Phase 4]
Phase 4 trial evaluating intravenous iron therapy in combination with erythropoiesis-stimulating agent for outcomes in chronic kidney diseas…
-
CLINICAL_TRIALS trial_result · 2023-01-05Clinical Trial Update: Renal Osteodystrophy: An Individual Management Approach [NA]
A completed clinical trial update discussing an individual management approach to renal osteodystrophy in chronic kidney disease.
-
CLINICAL_TRIALS trial_result · 2022-01-27Clinical Trial Update: Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure [Phase 3]
Phase III clinical study investigating recombinant erythropoiesis-stimulating protein (rESP) for anemia in patients with chronic kidney dise…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2021-12-09Clinical Trial Update: Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease [Phase 4]
A Phase 4 trial investigating left ventricular hypertrophy and spironolactone in chronic kidney disease has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-07-02Clinical Trial Update: Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease [Phase 4]
Phase 4 trial update reporting on efficacy and safety of Fosrenol for elevated serum phosphate in adults with end-stage renal disease.
-
CLINICAL_TRIALS trial_result · 2021-06-23Clinical Trial Update: A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol. [Phase 3]
Phase 3 long-term study of lanthanum carbonate in dialysis patients previously treated with the drug has completed.
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their Blood [Phase 3]
Phase 3 trial update on efficacy and safety of lanthanum for controlling serum phosphate in subjects with end-stage renal disease requiring …
-
CLINICAL_TRIALS trial_result · 2021-04-06Clinical Trial Update: Safety of Sofosbuvir in People With Advanced Kidney Failure [Phase 3]
A Phase 3 clinical trial update assessing the safety of Sofosbuvir in people with advanced kidney failure and chronic hepatitis C has comple…
-
EMA approval · 2020-11-25EMA Authorised: Silapo (epoetin zeta) — Stada Arzneimittel AG
Silapo (epoetin zeta) has been authorised by the EMA for indications related to anemia associated with chronic kidney disease, cancer, and u…
-
CLINICAL_TRIALS trial_result · 2020-01-13Clinical Trial Update: Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis [Phase 4]
Phase 4 trial assessing safety and efficacy of Nephoxil® in subjects with end-stage renal disease on dialysis.
-
CLINICAL_TRIALS research · 2019-02-11Clinical Trial Update: Improving Communication About Serious Illness [NA]
A completed clinical trial focusing on improving communication regarding serious illness and care planning.
-
CLINICAL_TRIALS trial_result · 2018-10-29Clinical Trial Update: A Study of LY2409021 in Participants With Different Levels of Kidney Function [Phase 1]
Phase 1 trial update of LY2409021 in participants with varying kidney function has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-12-20Clinical Trial Update: Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch [Phase 3]
A Phase 3 clinical trial evaluating induction therapy in live donor kidney transplant recipients with a positive crossmatch has completed; r…
-
CLINICAL_TRIALS trial_result · 2017-12-11Clinical Trial Update: Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation [Phase 4]
Phase 4 trial comparing pharmacokinetics of sublingual versus oral tacrolimus in patients awaiting kidney transplantation; results posted af…
-
CLINICAL_TRIALS trial_result · 2017-09-29Clinical Trial Update: Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects [Phase 1]
Phase 1 pharmacokinetics, pharmacodynamics, and safety study of ticagrelor in hemodialysis patients and healthy subjects completed; results …
-
CLINICAL_TRIALS trial_result · 2013-08-01Clinical Trial Update: Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy? [Phase 4]
Phase 4 trial evaluated whether an abnormal PFA-100 platelet function test predicts bleeding after renal biopsy; the study was terminated an…
-
CLINICAL_TRIALS trial_result · 2009-11-09Clinical Trial Update: Dynepo Long-Term Safety Study [Phase 4]
Phase 4 long-term safety study of Dynepo has been terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2009-09-28Clinical Trial Update: DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)
Clinical trial DELFT evaluating long-term treatment for anemia in kidney disease was terminated with results posted in 2009.
-
EMA withdrawal · 2009-01-28EMA Withdrawn: Nespo (darbepoetin alfa) — Dompé Biotec S.p.A.
EMA has withdrawn Nespo (darbepoetin alfa) from Dompé Biotec S.p.A.'s portfolio.